Indiana’s CBD hemp oil legislation, Senate Bill 15, targeting Hoosiers that suffer from “intractable epilepsy,” passed the state Senate on Tuesday by a vote of 38 to 12.
Indiana is one of the few remaining states to embrace the medical efficacy of cannabidiol (CBD).
Senate Bill 15 defines rigorous guidelines for physicians hoping to utilize a hemp-based CBD oil for the treatment of nonresponsive epilepsy, and establishes “a cannabidiol registry for certain physicians, nurses, individuals, and caregivers for the use of cannabidiol in the treatment of a person with intractable epilepsy.”
A pilot program, SB15 would create an educational registry for doctors who seek to study the use of cannabidiol in the treatment of intractable epilepsy.
If passed, the legislation would require Indiana’s department of health to develop and maintain the registries, and would provide civil, criminal, and administrative exemption from criminal penalties for those doctors and nurses who utilize CBD oil in the treatment of nonresponsive epilepsy for their patients, provided all requirements are met.
Authored by (R) Sen. James Tomes, (R) Sen. Michael Young, (R) Sen. Blake Doriot, SB 15 would also allow pharmacies to dispense CBD oil “subject to specific requirements.”
Most importantly, provided Senate Bill 15 becomes law, it would encourage state educational institutions to research the use of CBD in the treatment of other ailments that have proven to be nonresponsive to Western medicine.